KYMR
NASDAQ · Biotechnology
Kymera Therapeutics Inc
$127.87
-8.38 (-6.15%)
Performance
1D
—
1W
+0.98%
1M
+18.02%
3M
+17.77%
6M
+52.05%
1Y
+109.62%
YTD
+75.74%
Open$138.03
Previous Close$136.25
Day High$138.03
Day Low$125.02
52W High$130.05
52W Low$55.66
Volume—
Avg Volume738.3K
Market Cap10.39B
P/E Ratio—
EPS$-3.24
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$115.38
Above
SMA 200
$97.33
Above
RSI (14)
84.2
Overbought
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
29 analysts
Price Target
-75.7% upside
Current
$127.87
$127.87
Target
$31.03
$31.03
$20.33
$31.03 avg
$33.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 38.07M | 40.39M | 7.83B |
| Net Income | -302,272,288 | -288,641,972 | 335.40M |
| Profit Margin | -794.0% | -754.3% | 4.3% |
| EBITDA | -331,146,059 | -333,781,173 | 592.59M |
| Free Cash Flow | — | — | 369.62M |
| Rev Growth | -5.8% | -5.8% | +18.7% |
| Debt/Equity | 0.00 | 0.00 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |